This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ENMD-1198

CASI Pharmaceuticals, Inc.

Drug Names(s): ENMD-1198

Description: ENMD-1198, a new chemical entity (NCE) based on a modified chemicalstructure of 2-methoxyestradiol (2ME2), is designed to decrease metabolismwhile retaining 2ME2's multiple mechanisms of action, including inducingapoptosis, binding microtubules, and inhibiting HIF-1alpha. Study resultsdemonstrated that ENMD-1198 is an orally active, microtubule disrupting agentthat leads to arrest of cell division and apoptosis in tumor cells. Inaddition, ENMD-1198 also exerts antiangiogenic activity that furthercontributes to its overall antitumor effects.

Deal Structure: The intellectual property for ENMD-1198 is owned by EntreMed.

EntreMed and CASI
In June 2014, EntreMed announced that at its annual meeting of stockholders, stockholders voted in favor of changing the companys corporate name to CASI Pharmaceuticals, Inc.


ENMD-1198 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug